-
1
-
-
79251478039
-
Genomics and the continuum of cancer care
-
Feero, W.G. et al. Genomics and the continuum of cancer care. N. Engl. J. Med. 364, 340-350 (2011).
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 340-350
-
-
Feero, W.G.1
-
2
-
-
84861639653
-
Traversing the genomic landscape of prostate cancer from diagnosis to death
-
Hieronymus, H. & Sawyers, C.L. Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat. Genet. 44, 613-614 (2012).
-
(2012)
Nat. Genet.
, vol.44
, pp. 613-614
-
-
Hieronymus, H.1
Sawyers, C.L.2
-
3
-
-
41649114164
-
Enabling personalized cancer medicine through analysis of gene-expression patterns
-
DOI 10.1038/nature06915, PII NATURE06915
-
van't Veer, L.J. & Bernards, R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-570 (2008). (Pubitemid 351483370)
-
(2008)
Nature
, vol.452
, Issue.7187
, pp. 564-570
-
-
Van 't Veer, L.J.1
Bernards, R.2
-
4
-
-
73949136029
-
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade
-
Weigelt, B., Baehner, F.L. & Reis-Filho, J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263-280 (2010).
-
(2010)
J. Pathol.
, vol.220
, pp. 263-280
-
-
Weigelt, B.1
Baehner, F.L.2
Reis-Filho, J.S.3
-
5
-
-
81555199640
-
Microarrays in the 2010s: The contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction
-
Colombo, P.E., Milanezi, F., Weigelt, B. & Reis-Filho, J.S. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res. 13, 212 (2011).
-
(2011)
Breast Cancer Res.
, vol.13
, pp. 212
-
-
Colombo, P.E.1
Milanezi, F.2
Weigelt, B.3
Reis-Filho, J.S.4
-
6
-
-
28844441230
-
Cell signaling: A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis
-
DOI 10.1126/science.1116598
-
Janes, K.A., Albeck, J.G., Gaudet, S., Sorger, P.K., Lauffenburger, D.A. & Yaffe, M.B. A systems model of signaling identifies a molecular basis set for cytokineinduced apoptosis. Science 310, 1646-1653 (2005). (Pubitemid 41780781)
-
(2005)
Science
, vol.310
, Issue.5754
, pp. 1646-1653
-
-
Janes, K.A.1
Albeck, J.G.2
Gaudet, S.3
Sorger, P.K.4
Lauffenburger, D.A.5
Yaffe, M.B.6
-
7
-
-
34547146985
-
Network medicine-from obesity to the diseasome"
-
Barabási, A.L. Network medicine-from obesity to the "diseasome". N. Engl. J. Med. 357, 404-407 (2007).
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 404-407
-
-
Barabási, A.L.1
-
8
-
-
73949157882
-
Network-based drugs and biomarkers
-
Erler, J.T. & Linding, R. Network-based drugs and biomarkers. J. Pathol. 220, 290-296 (2010).
-
(2010)
J. Pathol.
, vol.220
, pp. 290-296
-
-
Erler, J.T.1
Linding, R.2
-
9
-
-
84860873858
-
Network medicine strikes a blow against breast cancer
-
Erler, J.T. & Linding, R. Network medicine strikes a blow against breast cancer. Cell 149, 731-733 (2012).
-
(2012)
Cell
, vol.149
, pp. 731-733
-
-
Erler, J.T.1
Linding, R.2
-
10
-
-
78650373804
-
Network medicine: A network-based approach to human disease
-
Barabási, A.L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68 (2011).
-
(2011)
Nat. Rev. Genet.
, vol.12
, pp. 56-68
-
-
Barabási, A.L.1
Gulbahce, N.2
Loscalzo, J.3
-
11
-
-
84866122803
-
Navigating cancer network attractors for tumor-specific therapy
-
Creixell, P., Schoof, E.M., Erler, J.T. & Linding, R. Navigating cancer network attractors for tumor-specific therapy. Nat. Biotechnol. 30, 842-848 (2012).
-
(2012)
Nat. Biotechnol.
, vol.30
, pp. 842-848
-
-
Creixell, P.1
Schoof, E.M.2
Erler, J.T.3
Linding, R.4
-
12
-
-
41149167511
-
Network medicine
-
Pawson, T. & Linding, R. Network medicine. FEBS Lett. 582, 1266-1270 (2008).
-
(2008)
FEBS Lett.
, vol.582
, pp. 1266-1270
-
-
Pawson, T.1
Linding, R.2
-
13
-
-
0016430104
-
Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
-
DeVita, V.T. Jr, Young, R.C. & Canellos, G.P. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35, 98-110 (1975).
-
(1975)
Cancer
, vol.35
, pp. 98-110
-
-
DeVita Jr., V.T.1
Young, R.C.2
Canellos, G.P.3
-
14
-
-
84863651163
-
Combinatorial drug therapy for cancer in the post-genomic era
-
Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
-
(2012)
Nat. Biotechnol.
, vol.30
, pp. 679-692
-
-
Al-Lazikani, B.1
Banerji, U.2
Workman, P.3
-
15
-
-
84881483492
-
Evolutionary dynamics of cancer in response to targeted combination therapy
-
Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2, e00747 (2013).
-
(2013)
Elife
, vol.2
-
-
Bozic, I.1
-
17
-
-
84860851412
-
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks
-
Lee, M.J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
-
(2012)
Cell
, vol.149
, pp. 780-794
-
-
Lee, M.J.1
-
18
-
-
54249155522
-
Network pharmacology: The next paradigm in drug discovery
-
Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
-
(2008)
Nat. Chem. Biol.
, vol.4
, pp. 682-690
-
-
Hopkins, A.L.1
-
19
-
-
69849115198
-
Therapeutically targeting ErbB3: A key node in ligandinduced activation of the ErbB receptor-PI3K axis
-
Schoeberl, B. et al. Therapeutically targeting ErbB3: a key node in ligandinduced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2, ra31 (2009).
-
(2009)
Sci. Signal.
, vol.2
-
-
Schoeberl, B.1
-
20
-
-
84888007494
-
-
Pipeline
-
Merrimack Pharamaceuticals. Pipeline. http://merrimackpharma.com/ solutions/pipeline .
-
Merrimack Pharamaceuticals
-
-
-
21
-
-
34547881522
-
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
-
DOI 10.1073/pnas.0705158104
-
Huang, P.H. et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. USA 104, 12867-12872 (2007). (Pubitemid 47255246)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.31
, pp. 12867-12872
-
-
Huang, P.H.1
Mukasa, A.2
Bonavia, R.3
Flynn, R.A.4
Brewer, Z.E.5
Cavenee, W.K.6
Furnari, F.B.7
White, F.M.8
-
22
-
-
73949083511
-
Oncogenic EGFR signaling networks in glioma
-
Huang, P.H., Xu, A.M. & White, F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2, re6 (2009).
-
(2009)
Sci. Signal.
, vol.2
-
-
Huang, P.H.1
Xu, A.M.2
White, F.M.3
-
23
-
-
84889002223
-
Network-based drug discovery by integrating systems biology and computational technologies
-
Leung, E.L., Cao, Z.W., Jiang, Z.H., Zhou, H. & Liu, L. Network-based drug discovery by integrating systems biology and computational technologies. Brief. Bioinformatics 14, 491-505 (2013).
-
(2013)
Brief. Bioinformatics
, vol.14
, pp. 491-505
-
-
Leung, E.L.1
Cao, Z.W.2
Jiang, Z.H.3
Zhou, H.4
Liu, L.5
-
24
-
-
66149091940
-
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
-
Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
-
(2009)
Cell
, vol.137
, pp. 835-848
-
-
Luo, J.1
-
25
-
-
77954938591
-
Future of personalized medicine in oncology: A systems biology approach
-
Gonzalez-Angulo, A.M., Hennessy, B.T. & Mills, G.B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777-2783 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2777-2783
-
-
Gonzalez-Angulo, A.M.1
Hennessy, B.T.2
Mills, G.B.3
-
26
-
-
34250743173
-
Systematic Discovery of In Vivo Phosphorylation Networks
-
DOI 10.1016/j.cell.2007.05.052, PII S0092867407007271
-
Linding, R. et al. Systematic discovery of in vivo phosphorylation networks. Cell 129, 1415-1426 (2007). (Pubitemid 46962092)
-
(2007)
Cell
, vol.129
, Issue.7
, pp. 1415-1426
-
-
Linding, R.1
Jensen, L.J.2
Ostheimer, G.J.3
Van Vugt, M.A.T.M.4
Jorgensen, C.5
Miron, I.M.6
Diella, F.7
Colwill, K.8
Taylor, L.9
Elder, K.10
Metalnikov, P.11
Nguyen, V.12
Pasculescu, A.13
Jin, J.14
Park, J.G.15
Samson, L.D.16
Woodgett, J.R.17
Russell Robert, B.18
Bork, P.19
Yaffe, M.B.20
Pawson, T.21
more..
-
27
-
-
72149101924
-
Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells
-
Jørgensen, C. et al. Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326, 1502-1509 (2009).
-
(2009)
Science
, vol.326
, pp. 1502-1509
-
-
Jørgensen, C.1
-
28
-
-
34250882643
-
Quantitative morphological signatures define local signaling networks regulating cell morphology
-
DOI 10.1126/science.1140324
-
Bakal, C., Aach, J., Church, G. & Perrimon, N. Quantitative morphological signatures define local signaling networks regulating cell morphology. Science 316, 1753-1756 (2007). (Pubitemid 46988551)
-
(2007)
Science
, vol.316
, Issue.5832
, pp. 1753-1756
-
-
Bakal, C.1
Aach, J.2
Church, G.3
Perrimon, N.4
-
29
-
-
54249117296
-
Phosphorylation networks regulating JNK activity in diverse genetic backgrounds
-
Bakal, C. et al. Phosphorylation networks regulating JNK activity in diverse genetic backgrounds. Science 322, 453-456 (2008).
-
(2008)
Science
, vol.322
, pp. 453-456
-
-
Bakal, C.1
-
30
-
-
33751547539
-
How many drug targets are there?
-
DOI 10.1038/nrd2199, PII NRD2199
-
Overington, J.P., Al-Lazikani, B. & Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006). (Pubitemid 44835126)
-
(2006)
Nature Reviews Drug Discovery
, vol.5
, Issue.12
, pp. 993-996
-
-
Overington, J.P.1
Al-Lazikani, B.2
Hopkins, A.L.3
-
31
-
-
59849106371
-
Protein promiscuity and its implications for biotechnology
-
Nobeli, I., Favia, A.D. & Thornton, J.M. Protein promiscuity and its implications for biotechnology. Nat. Biotechnol. 27, 157-167 (2009).
-
(2009)
Nat. Biotechnol.
, vol.27
, pp. 157-167
-
-
Nobeli, I.1
Favia, A.D.2
Thornton, J.M.3
-
32
-
-
70449673534
-
Drug discovery: Predicting promiscuity
-
Hopkins, A.L. Drug discovery: Predicting promiscuity. Nature 462, 167-168 (2009).
-
(2009)
Nature
, vol.462
, pp. 167-168
-
-
Hopkins, A.L.1
-
33
-
-
38049018155
-
A quantitative analysis of kinase inhibitor selectivity
-
Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
-
(2008)
Nat. Biotechnol.
, vol.26
, pp. 127-132
-
-
Karaman, M.W.1
-
34
-
-
80755125575
-
Comprehensive analysis of kinase inhibitor selectivity
-
Davis, M.I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
-
(2011)
Nat. Biotechnol.
, vol.29
, pp. 1046-1051
-
-
Davis, M.I.1
-
35
-
-
80755125565
-
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
-
Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H. & Peterson, J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045 (2011).
-
(2011)
Nat. Biotechnol.
, vol.29
, pp. 1039-1045
-
-
Anastassiadis, T.1
Deacon, S.W.2
Devarajan, K.3
Ma, H.4
Peterson, J.R.5
-
36
-
-
32344446028
-
Can we rationally design promiscuous drugs?
-
DOI 10.1016/j.sbi.2006.01.013, PII S0959440X06000157
-
Hopkins, A.L., Mason, J.S. & Overington, J.P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127-136 (2006). (Pubitemid 43221881)
-
(2006)
Current Opinion in Structural Biology
, vol.16
, Issue.1
, pp. 127-136
-
-
Hopkins, A.L.1
Mason, J.S.2
Overington, J.P.3
-
37
-
-
84857411100
-
The prevalence and cost of unapproved uses of top-selling orphan drugs
-
Kesselheim, A.S., Myers, J.A., Solomon, D.H., Winkelmayer, W.C., Levin, R. & Avorn, J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS ONE 7, e31894 (2012).
-
(2012)
PLoS ONE
, vol.7
-
-
Kesselheim, A.S.1
Myers, J.A.2
Solomon, D.H.3
Winkelmayer, W.C.4
Levin, R.5
Avorn, J.6
-
38
-
-
82255192307
-
Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects
-
Lötsch, J. & Geisslinger, G. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. Drug Discov. Today 16, 1001-1006 (2011).
-
(2011)
Drug Discov. Today
, vol.16
, pp. 1001-1006
-
-
Lötsch, J.1
Geisslinger, G.2
-
39
-
-
84884162850
-
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors
-
Kirouac, D.C. et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 6, ra68 (2013).
-
(2013)
Sci. Signal.
, vol.6
-
-
Kirouac, D.C.1
-
40
-
-
33746156959
-
Global mapping of pharmacological space
-
DOI 10.1038/nbt1228, PII NBT1228
-
Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S. & Hopkins, A.L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815 (2006). (Pubitemid 44086621)
-
(2006)
Nature Biotechnology
, vol.24
, Issue.7
, pp. 805-815
-
-
Paolini, G.V.1
Shapland, R.H.B.2
Van Hoorn, W.P.3
Mason, J.S.4
Hopkins, A.L.5
-
41
-
-
78651287426
-
DrugBank 3.0: A comprehensive resource for 'omics' research on drugs
-
Knox, C. et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).
-
(2011)
Nucleic Acids Res.
, vol.39
-
-
Knox, C.1
-
42
-
-
84860492047
-
CanSAR: An integrated cancer public translational research and drug discovery resource
-
Halling-Brown, M.D., Bulusu, K.C., Patel, M., Tym, J.E. & Al-Lazikani, B. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947-D956 (2012).
-
(2012)
Nucleic Acids Res.
, vol.40
-
-
Halling-Brown, M.D.1
Bulusu, K.C.2
Patel, M.3
Tym, J.E.4
Al-Lazikani, B.5
-
43
-
-
84862192766
-
ChEMBL: A large-scale bioactivity database for drug discovery
-
Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012).
-
(2012)
Nucleic Acids Res.
, vol.40
-
-
Gaulton, A.1
-
44
-
-
59349116903
-
Knocking down barriers: Advances in siRNA delivery
-
Whitehead, K.A., Langer, R. & Anderson, D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138 (2009).
-
(2009)
Nat. Rev. Drug Discov.
, vol.8
, pp. 129-138
-
-
Whitehead, K.A.1
Langer, R.2
Anderson, D.G.3
-
45
-
-
84856389509
-
RNA-based therapeutics: Current progress and future prospects
-
Burnett, J.C. & Rossi, J.J. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19, 60-71 (2012).
-
(2012)
Chem. Biol.
, vol.19
, pp. 60-71
-
-
Burnett, J.C.1
Rossi, J.J.2
-
46
-
-
84874443644
-
Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo
-
Meng, H. et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7, 994-1005 (2013).
-
(2013)
ACS Nano
, vol.7
, pp. 994-1005
-
-
Meng, H.1
-
47
-
-
84866096861
-
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators
-
Bodenmiller, B. et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat. Biotechnol. 30, 858-867 (2012).
-
(2012)
Nat. Biotechnol.
, vol.30
, pp. 858-867
-
-
Bodenmiller, B.1
-
48
-
-
84879796970
-
Circulating tumour cells and cell-free DNA as tools for managing breast cancer
-
Cortes, J. et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 10, 377-389 (2013).
-
(2013)
Nat. Rev. Clin. Oncol.
, vol.10
, pp. 377-389
-
-
Cortes, J.1
-
49
-
-
84881479047
-
Liquid biopsy: Monitoring cancer-genetics in the blood
-
Crowley, E., Di Nicolantonio, F., Loupakis, F. & Bardelli, A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10, 472-484 (2013).
-
(2013)
Nat. Rev. Clin. Oncol.
, vol.10
, pp. 472-484
-
-
Crowley, E.1
Di Nicolantonio, F.2
Loupakis, F.3
Bardelli, A.4
-
50
-
-
77954113465
-
Predicting and monitoring cancer treatment response with diffusion-weighted MRI
-
Thoeny, H.C. & Ross, B.D. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J. Magn. Reson. Imaging 32, 2-16 (2010).
-
(2010)
J. Magn. Reson. Imaging
, vol.32
, pp. 2-16
-
-
Thoeny, H.C.1
Ross, B.D.2
-
51
-
-
66149097035
-
Response to therapy in breast cancer
-
Avril, N., Sassen, S. & Roylance, R. Response to therapy in breast cancer. J. Nucl. Med. 50 (suppl. 1), 55S-63S (2009).
-
(2009)
J. Nucl. Med.
, vol.50
, Issue.SUPPL. 1
-
-
Avril, N.1
Sassen, S.2
Roylance, R.3
|